# iPSC

The Great Leap for Regenerative Medicine: Japan’s Regulatory Gamble Sparks a Global iPSC Race

The global iPSC therapy market has entered a critical clinical phase following Japan's landmark 2026 conditional approvals for heart failure and Parkinson's treatments. While breakthroughs in China and the US demonstrate the curative potential for chronic diseases, the industry must now solve the dual challenges of high manufacturing costs and regulatory safety monitoring.

NeTe2026年4月16日 03:29

#iPSC#Regenerative Medicine#Parkinson's Disease

Blurred unrecognizable person placing sample on microscope while making research during work in modern laboratory

Science

Neural Rewiring: Shanghai Biotech Secures Global First with Dual US-China Approval for Epilepsy Cell Therapy

Shanghai's Yuesai Biotechnology has become the first company globally to receive IND approval from both the US FDA and China's CDE for an iPSC-derived cell therapy targeting refractory epilepsy, marking a major breakthrough in regenerative medicine.

NeTe2026年4月9日 02:29

#Biotechnology#iPSC#Epilepsy